Cambridge Design Partnership

Cambridge Design Partnership is an independent innovation partner that designs and engineers drug delivery systems, as well as diagnostics, surgical equipment, and other health-related products. It has completed >1,000 product development assignments for business around the world.

Head Office
Cambridge Design Partnership Ltd
Church Road
Toft
Cambridge
CB23 2RF
United Kingdom

Phone / Contact

T: +44 1223 264428
F: +44 1223 265749

Connect

Cambridge Design Partnership (CDP) is an end-to-end innovation partner focused on helping clients grow. Some of the world’s largest companies trust CDP to design and develop their most important innovations. Located in Cambridge (UK) and Raleigh (NC, US), CDP specialises in the consumer, healthcare and industrial markets. Its multidisciplinary teams have expert knowledge to identify opportunities and overcome challenges throughout the product development and manufacturing process.

CDP is privately owned and was founded in the early 2000s.

Articles by Cambridge Design Partnership

TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY

Mark Allen, Andrew Fiorini and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper.

ISO 11608: WHAT THE NEW STANDARD MEANS FOR NIS MANUFACTURERS

Steve Augustyn looks at ISO 11608 and what it means for needle-based injection device manufacturers.

THE SMART INHALER REVOLUTION: ARE WE THERE YET?

Mark Allen, David Blakey and Karla Sanchez discuss the benefits of smart inhalers and how they could influence the commercialisation of respiratory drugs in the future.

SUSTAINABILITY: WHAT CAN THE HEALTHCARE SECTOR LEARN FROM CONSUMER DESIGN?

Fran Penrose considers the lessons the healthcare sector can draw from the fast-moving consumer sector when designing for sustainability and asks, “Can we go even further?”

WAITING FOR THE OUTBREATH – WHAT CAN COVID-19 BIOAEROSOL RESEARCH TELL US ABOUT INHALABLE DRUG DELIVERY?

Deborah Norris, Mark Allen, Karl Hewson and Karla Sanchez, discuss how the covid-19 pandemic has spurred research in the pulmonary space, which suggests that a patient-tailored approach based on their individual lung characteristics, facilitated by advanced technology, could improve patient health outcomes and quality of life.

Caroline Zakrzewski

FORMULATION & DEVICE DEVELOPMENT: A SYMBIOTIC RELATIONSHIP

Caroline Zakrzewski considers the interaction between formulation and device development and the challenges that drive innovation in the field. Her work frequently sits in the overlap between formulation and device development, navigating the interwoven steps that lead to the sweet spot, where formulation and a device work in tandem, providing safe and effective delivery of the drug.

RETHINKING DRUG DELIVERY DEVICES FOR SUSTAINABILITY AND INNOVATION

Sergio Malorni and George Bostock discuss the issue of designing for sustainability, including going beyond “Reduce, Reuse, Recycle” to “Rethink” and looking to adjacent and consumer industries for inspiration on innovations the drug delivery industry can adopt with a view to reducing its environmental impact.

María Fernández-Martos Balson

THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS

María Fernández-Martos Balson and Bastiaan De Leeuw explore the oral delivery of biologics and the challenges that must be overcome in order to enhance bioavailability. The authors also take a look at some recently developed drug-device combinations.

INTERVIEW WITH STEVEN KAUFMAN, STEVANATO & URI BARUCH, CDP

Steven Kaufman and Uri Baruch discuss the recently announced collaboration between their two companies to accelerate the development of a new variable-dose, cartridge-based pen injector platform for diabetes.

HOW A DIGITAL APPROACH CAN UNPICK CLINICAL TRIAL CHALLENGES AND IMPROVE OUTCOMES

Matt Ash, Tom Lawrie-Fussey and Bastiaan De Leeuw look at the role digital technology can play in the development of drug-device combination products.

SIX TECHNIQUES FOR RAPID EARLY-STAGE MEDICAL DEVICE DEVELOPMENT

Stuart Curtis runs through six techniques which, in his experience, are invaluable for accelerating the early development stages of drug delivery device design and can therefore be of great use when trying to accelerate a product’s time to market.

Tom Lawrie-Fussey

WE’RE OFF TO SEE THE WIZARD: “USE-LIKE” PROTOTYPING OF DIGITAL CONCEPTS

Tom Lawrie-Fussey and Lucy Sheldon introduce “Wizard of Oz” testing, named after the classic novel and film, whereby experimenters can field test concepts at a very early stage by giving the illusion of a finished product, saving potential costly and time-consuming changes further along the development process.

A “KODAK” MOMENT FOR THE PHARMA INDUSTRY?

Pari Datta and Nick Rollings discuss the concept of personalised medicine, with particular reference to oncology, and how it represents both an opportunity and a threat.

Tom Lawrie-Fussey

THE SMART APPROACH TO HARNESSING DATA

As the drug delivery world moves to embrace big data, it is important to remember that unseen risks await the unwary. Tom Lawrie-Fussey explains further.

THE FUTURE OF DRUG DELIVERY

Uri Baruch looks back on how far injectable drug delivery has come in the past thirty years and, with an eye on current trends and the range of innovations in the sector, particularly data and connectivity technology, looks forward to what the future may hold.

A PATIENT-CENTRIC APPROACH TO THERAPY MANAGEMENT

Karl Hewson and Uri Baruch discuss the challenges presented by chronic illness, and look ahead to a better future of patient-centric treatment, personalised to each individual’s needs.

THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR

Ryan Noble and Tom Lawrie-Fussey discuss the potential of digital innovations to improve understanding of real patient behaviour and consequently increase adherence.

DOES THE NEW EU MDR SPELL THE END OF GRANDFATHERING?

Helen Simons and Stephanie Ward describe how the new EU Medical Devices Regulation will impact on “grandfathered” devices that were approved under old regulation and are currently on the market, but do not necessarily comply with current/updated regulatory standards, and explain the potential implications for device manufacturers.

Top